A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

NCT03107026 PHASE3 COMPLETED Results posted

A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder

Details

Lead sponsor	Sumitomo Pharma America, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	491
Start date	Fri Mar 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Binge Eating Disorder

Interventions

• dasotraline 4mg
• dasotraline 6mg
• Placebo

Countries

United States